2234. Outcomes by Age and Gender from a Global Phase 3 Study of Delafloxacin (DLX) in Community-Acquired Bacterial Pneumonia (CABP)

BACKGROUND: Delafloxacin (DLX) is a fluoroquinolone, approved in the United States for treatment of ABSSSI. DLX has no preclinical signals for QT prolongation and has no QT prolongation in a validated challenge study. Risk of QT prolongation is a consideration in antibiotic selection for elderly hos...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Open Forum Infect Dis
Huvudupphovsmän: Madej, Andrzej, Pullman, John, Popescu, Monica, Quintas, Megan, Lawrence, Laura, Li, Yang, Cammarata, Sue
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2019
Ämnen:
Abstracts
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6810084/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1912
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk